阿尔采末病治疗药物的研究展望  

Advances in studies of drug treatment of Alzheimer's disease

作　　者：阮志[1] 章海燕[1] 

机构地区：[1]中国科学院上海药物研究所新药研究国家重点实验室,上海201203

出　　处：《中国新药与临床杂志》2012年第4期175-187,共13页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：阿尔采末病(AD)是老年痴呆最常见类型,以高发病率、高致死率著称。尽管目前还缺乏公认的针对疾病病因的关键靶标,通过干预β淀粉样蛋白(Aβ)级联反应假说涉及的各环节发挥预期疗效仍为当前的热点研究方向之一,尤其是抑制Aβ寡聚化以及通过外周系统清除Aβ的干预策略。研究表明,一些针对Aβ相关通路的靶向药物研究取得了可喜的进展;与此同时,在线粒体功能紊乱、神经营养因子、多靶点治疗研究中的新发现进一步拓展了AD治疗策略的研究领域,这些必将会加快寻找新型高效AD治疗药物的步伐。本文综述了近年来AD治疗药物的重要研究进展,对当前研究中面临的挑战进行了探讨,并对今后研究动向作了简要展望,以期为未来AD治疗药物的开发及应用提供重要线索和依据。Alzheimer＇s disease （AD）, the most common form of dementia in the elderly, is a neurodegenerative disorder which characterized by high morbidity and mortality rate. Although it is still short of well-recognized molecular target for blocking the pathogenesis of the disease, interfering different steps involved in the amyloid β （Aβ） cascade hypothesis remains as one of the hot research areas, especially those reducing Aβ oligomerization and clearing Aβ through peripheral system. Up to date, intervention in Aβ pathways has made gratifying progress and obtained some targeted drug candidates; meanwhile, new discoveries in mitochondrial dysfunction, neurotrophic factor and multiple-target treatments also have further expanded the field of AD therapeutic strategy, all of these will certainly accelerate the pace of finding novel effective AD drug. This review summarized the progress in research and development of AD drug, the current research challenges, as well as the prospect of research trends, to provide important clues and evidences for the development and application of future AD drugs.

关 键 词：阿尔茨海默病 候选药物 药物评价 临床试验 药物毒性 

分 类 号：R964[医药卫生—药理学] R971[医药卫生—药学]